Biosimilars Brain Cancer Breast CancerBreast Cancer CAR T-cell Therapy COVID-19 Disparities in Cancer Care Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer Genitourinary CancersGenitourinary CancersGenitourinary Cancers ...
Introduction: In 2019, the PD-L1 inhibitor atezolizumab became the first immune checkpoint inhibitor approved for treatment in patients with breast cancer. The approval is restricted to patients with metastatic triple-negative breast cancer (TNBC) whose tumors are PD-L1 positive. There is a ...
remove all or part of your kidney and also surgery to remove cancer that has spread to other parts of the body (metastatic lesions). a kind of uterine cancer called advanced endometrial carcinoma. It may be used with the chemotherapy medicines carboplatin and paclitaxel, and then may be used...
Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina Apr 17th 2025 - May 23rd 2025 online-activity View More Video Addressing Unmet Needs in HER2+ Metastatic BTC Apr 24th 20...
Immunochemotherapy with pembrolizumab has been integrated into clinical practice as part of the standard-of-care for non-metastatic triple-negative breast cancer (TNBC) with high risk. We conducted a real-world study in TNBC patients treated with neoadjuvant chemotherapy to compare pathologic complete ...
Briefly, eligible patients were 18 years or older with centrally confirmed, newly diagnosed, previously untreated, nonmetastatic TNBC (tumor stage T1c, nodal stage N1-2 or tumor stage T2-4, nodal stage N0-2 per the American Joint Committee on Cancer20) as determined by investigator ...
The randomized, double-blind trial enrolled patients at least 18 years of age with centrally confirmed TNBC in all foci. Patients needed to have newly diagnosed, previously untreated, nonmetastatic disease, defined as tumor stage T1c, nodal stage N1-2, or tumor stage T2-4, nodal stage N0...
In KEYNOTE-355, when KEYTRUDA and chemotherapy (paclitaxel, paclitaxel protein-bound, or gemcitabine and carboplatin) were administered to patients with locally recurrent unresectable or metastatic TNBC who had no...
In KEYNOTE-355, when KEYTRUDA and chemotherapy (paclitaxel, paclitaxel protein-bound, or gemcitabine and carboplatin) were administered to patients with locally recurrent unresectable or metastatic TNBC who had not ...
Updated Guidelines Recommend Adding Pembrolizumab to Neoadjuvant Chemotherapy in TNBC Positive Outcomes of Novel Cellular Therapies Are Seen in Long Relapse, DLBCL Minimal Difference in Efficacy Shown for Immunotherapy Combos in Poor-Performance Metastatic RCC Circulating Tumor DNA Provides Potential Th...